The National Institutes of Health (NIH) has announced a funding opportunity titled “Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)” under the opportunity number PAR-24-068. This discretionary grant is dedicated to supporting research on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The program has an award ceiling of $350,000 and is open for applications until November 16, 2026.
The goal of this funding opportunity is to advance research in two key areas: (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD, and (2) interventions for individuals with FASD. The funding mechanism, the Exploratory/Developmental Phased Award (R61/R33), will support pilot studies, secondary data analysis for hypothesis development, and feasibility research in the R61 phase, with the possibility of expanding into more extensive research testing in the R33 phase. This initiative represents a critical effort in addressing the challenges associated with FASD and aims to contribute significantly to the development of effective prevention and intervention strategies.
Opportunity ID: 351108
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-068 |
| Funding Opportunity Title: | Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | |
| Expected Number of Awards: | |
| CFDA Number(s): | 93.273 — Alcohol Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 22, 2023 |
| Last Updated Date: | Nov 22, 2023 |
| Original Closing Date for Applications: | Nov 16, 2026 |
| Current Closing Date for Applications: | Nov 16, 2026 |
| Archive Date: | Dec 22, 2026 |
| Estimated Total Program Funding: | |
| Award Ceiling: | $350,000 |
| Award Floor: | $ |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Small businesses For profit organizations other than small businesses Independent school districts Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Private institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-068.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information
grantsinfo@nih.gov |